Masked Antibodies & Cytokines as Prodrugs - October 2021 Industry Landscape: Stakeholders, Technologies, Pipelines, Business and Financing

News provided by

Oct 14, 2021, 14:15 ET

DUBLIN, Oct. 14, 2021 /PRNewswire/ -- The "Masked Antibodies & Cytokines as Prodrugs: A Landscape Analysis of Stakeholders, Technologies, Pipelines, Business and Financing from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.

This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology platforms from an industry perspective.

The prodrug concept of masking technologies is an elegant approach to address the selectivity limitations of conventional therapeutic antibodies and cytokines.

The report brings you up-to-date with information about and analysis of:

Stakeholders in the field: technology and major pharmaceutical companies and investors;
Masking technologies: conventional (kinetically controlled); pH-dependent and protease cleavage in the tumor microenvironment
Targets of masked antibodies and type of masked cytokine selected for development of masked biologics;
Business strategy: pure-play (foundational or converted) masking technology company, diversified technology company, exit options, preferred antibody modality or type of cytokine, investment case;
Financing situation of technology companies and key investors in the field;
Partnering deals with financial terms;
Major pharmaceutical companies: preferences for masking technologies, collaboration, and licensing agreements.

Market Summary

Therapeutic antibodies have become a clinically and commercially successful treatment modality with more than 100 antibodies approved for therapy and commercial sales of more than US$ 184 billion in the year 2020. However, systemic administration of monoclonal antibodies or cytokines may induce severe adverse events with mechanism-of-action effects, meaning off-tumor on-target toxicity in healthy tissue.

In order to increase the selectivity of antibodies and cytokines at the disease site, antibodies should ignore the target antigen and cytokines the receptor in normal healthy tissue and be preferentially active in the disease region. The use of antibody prodrugs is one new strategy for more specific tumor targeting of biological therapies.

What will you find in the report?

Profiles of antibody & cytokine masking technology companies active in the field;
Description of major pharma's/biotech's role in the field (in-house R&D, partnering and investing);
Comprehensive description and analysis of emerging masked antibodies and cytokines;
Pharmacologic profiles of selected masked antibodies and cytokines;
Characterization, profiling and state of antibody & cytokine masking technologies;
Target selection for each antibody masking technology;
Selection of type of cytokine for each cytokine masking technology;
Description and analysis of financing rounds (capital raised, investors);
Economic terms of collaboration and licensing deals;
Sources of financing.

Key Topics Covered

1 Executive Summary

2 Introduction, Overview & Methodology

3 Stakeholder Analysis
3.1 Overview
3.2 Masking Technology Companies
3.3 Pharma/Biotech Companies Partnered with Masking Technology Companies

4 Profiles of Stakeholders in Masking Technologies
4.1 Profiles of Masking Technology Companies
4.1.1 Accurus Bioscience
4.1.2 Adagene
4.1.3 Amunix Pharmaceuticals
4.1.4 Ascendis Pharma
4.1.5 AskGene Pharma
4.1.6 BioAtla
4.1.7 Bright Peak Therapeutics
4.1.8 CytomX Therapeutics
4.1.9 GlycoNEX
4.1.10 Harpoon Therapeutics
4.1.11 Janux Therapeutics
4.1.12 Maverick Therapeutics
4.1.13 Meditope Biosciences
4.1.14 Molecular Partners
4.1.15 Nektar Therapeutics
4.1.16 Revitope Oncology
4.1.17 SeaGen
4.1.18 Shanghai Affinity Biopharmaceutical
4.1.19 Tansoar Biotech
4.1.20 Trutino Biosciences
4.1.21 Werewolf Therapeutics
4.1.22 Xilio Therapeutics
4.1.23 Zymeworks
4.2 Profiles of Pharma & Biotech Companies with a Stake in Masking Technologies
4.2.1 AbbVie
4.2.2 ADC Therapeutics
4.2.3 Amgen
4.2.4 Astellas Pharma
4.2.5 BeiGene
4.2.6 Boehringer Ingelheim
4.2.7 Bristol Myers Squibb
4.2.8 Exelixis
4.2.9 I-Mab Biopharma
4.2.10 Immunogen
4.2.11 Janssen
4.2.12 Junshi Biosciences
4.2.13 Merck
4.2.14 Mitsubishi Tanabe Pharma
4.2.15 Pfizer
4.2.16 Roche
4.2.17 Takeda Pharmaceutical Co

5 Analysis of Masking Technologies
5.1 Origin of Masking Technologies
5.2 Prodrug Antibody Technologies
5.3 Prodrug Cytokine Technologies
5.4 Prodrug Antibody & Cytokine Technologies

6 Profiles of Masking Technologies
6.1 Masking Technologies Applied Only to Antibodies
6.2 Masking Technologies Applied Only To Cytokines
6-2.5 Trutino Biosciences: On-Demand-Cytokine (ODC) Platform
6.3 Masking Technologies Applied to Antibodies & Cytokines

7 Analysis of Pipeline and Masked Antibody & Cytokine Prodrug Candidates
7.1 Introduction
7.2 Analysis of the Pipeline of Masked Antibodies
7.3 Analysis of the Pipeline of Masked Cytokines

8 Profiles of Masked Antibody & Cytokine Product Candidates
8.1 Masked Immuno-Oncology Antibodies
8.2 Masked Antibody-Drug Conjugates
8.3 Masked T-Cell Engaging (TCE) Antibodies
8.4 Masked Interleukin-2 (IL-2) Cytokines
8.5 Masked Interleukin-12 (IL-12) and -15 (IL-15) Cytokines
8.6 Masked Interferon (IFN) Cytokines

9 Business, Financing & Partnering
9.1 Business
9.2 Financing
9.3 Partnering

For more information about this report visit https://www.researchandmarkets.com/r/yq71z0

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets